JNJ vs AZN stock comparison
Johnson & Johnson vs. Astrazeneca · data as of November 13, 2026
Johnson & Johnson (JNJ) has a market value of about $687.9B, Astrazeneca (AZN) about $286.0B. Over their latest twelve months Johnson & Johnson had revenue of $99.3B and Astrazeneca $62.4B.
On our five checks Astrazeneca scores higher: 2.8 out of 5 (average) against 2.6 (average).
By area, the stronger company is Astrazeneca on value; Astrazeneca on future growth; Johnson & Johnson on financial health; Johnson & Johnson on shareholder returns.
Astrazeneca is cheaper on earnings (P/E 26.1 vs. 43.4).
Johnson & Johnson leads on 8 of the compared lines and Astrazeneca on 16.
Side by side
| JNJ | AZN | |
|---|---|---|
| Size and price | ||
| Market cap | $687.9B | $286.0B |
| Share price | $285.75 | $184.45 |
| Score | ||
| Overall score (of 5) | 2.6 | 2.8 |
| Value | 0 | 1 |
| Future growth | 0 | 2 |
| Track record | 4 | 4 |
| Financial health | 4 | 3 |
| Shareholder returns | 5 | 4 |
| Valuation | ||
| P/E (TTM) | 43.4 | 26.1 |
| Forward P/E | 25.1 | 16.5 |
| Price / free cash flow | 33.4 | 46.9 |
| Price / sales | 6.9 | 4.6 |
| EV / EBITDA | 26.7 | 14.7 |
| PEG | 2.91 | 1.20 |
| DCF value vs. price | −39% | −38% |
| Business | ||
| Revenue | $99.3B | $62.4B |
| Net income | $16.1B | $11.0B |
| Free cash flow | $20.6B | $6.1B |
| Net margin | 16.2% | 17.7% |
| Gross margin (5-yr avg.) | 69.1% | 76.8% |
| ROIC (5-yr avg.) | 16.6% | 8.4% |
| Growth | ||
| Revenue growth (1 yr) | 6.0% | 8.6% |
| Revenue growth (5 yrs, per year) | 2.7% | 17.2% |
| EPS growth (5 yrs, per year) | 14.9% | 21.8% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$27.4B | -$26.0B |
| Dividend yield | 1.88% | 1.74% |
| Shareholder yield | 2.8% | 1.9% |
| Analysts | ||
| Upside to average target | −2% | +13% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: JNJ TTM to September 27, 2026, AZN TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Johnson & Johnson or Astrazeneca?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Astrazeneca scores 2.8 out of 5 and Johnson & Johnson 2.6; the table shows where each one is stronger.
Is Johnson & Johnson cheaper than Astrazeneca?
On trailing earnings, Astrazeneca trades at a P/E of 26.1 and Johnson & Johnson at 43.4, so Astrazeneca is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Johnson & Johnson or Astrazeneca?
Over five years Astrazeneca grew revenue about 17.2% a year and Johnson & Johnson about 2.7% a year.
Which pays a higher dividend?
Johnson & Johnson yields 1.88% and Astrazeneca 1.74%.
Full Johnson & Johnson analysis → Full Astrazeneca analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.